Takashi Ohta
Overview
Explore the profile of Takashi Ohta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
1196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwamoto T, Nozaki Y, Inoue T, Suda T, Mizumoto R, Arimoto Y, et al.
J Gastroenterol
. 2024 Nov;
60(2):197-209.
PMID: 39585387
Background: The histological improvement in liver fibrosis in patients with hepatitis C who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) treatment has not been comprehensively investigated. Therefore,...
2.
Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, et al.
BJC Rep
. 2024 Nov;
2(1):54.
PMID: 39516322
Background: While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess...
3.
Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, et al.
Nat Med
. 2024 Sep;
31(1):165-175.
PMID: 39284955
Although comprehensive genomic profiling has become standard in oncology for advanced solid tumors, the full potential of circulating tumor DNA (ctDNA)-based profiling in capturing tumor heterogeneity and guiding therapy selection...
4.
Nakamura Y, Tsukada Y, Matsuhashi N, Murano T, Shiozawa M, Takahashi Y, et al.
Clin Cancer Res
. 2024 Aug;
30(19):4377-4387.
PMID: 39110016
Purpose: Posttreatment detection of ctDNA is strongly predictive of recurrence. Most minimal/molecular residual disease assays require prior tissue testing to guide ctDNA analysis, resulting in lengthy time to initial results...
5.
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, et al.
Target Oncol
. 2024 Mar;
19(2):181-190.
PMID: 38427280
Background: Non-inferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) to irinotecan/fluoropyrimidine plus BEV in metastatic colorectal cancer was investigated in the phase III TRUSTY study, and we conducted a phase II...
6.
Kajiwara T, Nishina T, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958346
The treatment strategies and prognoses of patients with metastatic colorectal cancer (CRC) differ according to the sidedness of the primary tumor. gain-of-function (GOF) and non-GOF variants have been reported to...
7.
Kito Y, Kawakami H, Mitani S, Nishina S, Matsumoto T, Tsuzuki T, et al.
Oncologist
. 2023 Nov;
29(3):e330-e336.
PMID: 37950903
Background: Trifluridine/tipiracil (FTD/TPI) plus bevacizumab has shown clinical benefit for metastatic colorectal cancer (mCRC) refractory to standard therapy. However, few data have been available for patients with pretreated mCRC who...
8.
Iwamoto T, Suda T, Inoue T, Nozaki Y, Mizumoto R, Arimoto Y, et al.
PLoS One
. 2023 Aug;
18(8):e0288463.
PMID: 37594942
This study aimed to investigate the bleeding risk associated with percutaneous transhepatic gallbladder interventions in patients with acute cholecystitis receiving antithrombotic therapy. In this retrospective study, 194 consecutive patients who...
9.
Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, et al.
Br J Cancer
. 2023 Aug;
129(6):1032-1039.
PMID: 37532830
Background: Although nivolumab has a high efficacy, reliable biomarkers are needed to predict the efficacy. We evaluated the nivolumab efficacy according to the TP53 mutation in advanced gastric cancer patients...
10.
Aoki Y, Nakamura Y, Denda T, Ohta T, Esaki T, Shiozawa M, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200688.
PMID: 37343204
Purpose: Circulating tumor DNA (ctDNA) genotyping on the basis of next-generation sequencing (NGS) may guide targeted therapy for metastatic colorectal cancer (mCRC). However, the validity of NGS-based ctDNA genotyping for...